National Institutes of Health

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Resvita Bio is a biotechnology company focused on developing and manufacturing engineered probiotics specifically designed to treat various skin-related diseases, including cancer. The company utilizes synthetic biology and metabolic engineering to create a versatile skin microbial platform. This platform aims to deliver therapies that reduce inflammation, repair damaged tissue, and eliminate harmful bacteria, offering faster and more effective treatment options for chronic skin conditions.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing microRNA (miRNAs) therapeutics for treating metastatic cancer. The company's core focus lies in its proprietary TTX nanoparticle platform, which enables the intelligent design and effective delivery of RNA therapeutics targeting specific miRNAs. TransCode's lead candidate, TTX-MC138, targets microRNA-10b, a validated biomarker of metastasis across multiple tumor types. By inhibiting this miRNA, TransCode aims to eradicate metastatic tumor cells and combat cancer progression.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Matter Bio is a biotechnology company dedicated to preserving genomic integrity. It offers research services aimed at enhancing longevity by safeguarding and utilising DNA information. The company's primary focus is assembling an elite team of scientists and executives to combat genetic mutations and extend patient lifespan through innovative approaches to reverse such mutations.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Golden Helix is a developer of bioinformatics solutions specializing in genomic data analysis, with a focus on supporting life science research and translational medicine. With over 20 years of experience, the company provides innovative cloud-based software that empowers scientists and healthcare professionals to manage, analyze, and visualize complex genomic and phenotypic data. By streamlining the annotation and filtering of variants from next-generation sequencing, Golden Helix enables biologists and researchers of varying expertise to conduct intricate analyses and produce meaningful insights from large genomic datasets without the constant need for specialized bioinformatics support.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.

Talus Bio is a biotechnology startup focused on drug discovery and development, particularly targeting challenging cancer transcription factors. The company employs an innovative approach that integrates functional proteomics, automated biology, and machine learning. Their MARMOT platform utilizes AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics. This platform is designed to advance drug development for gene regulation in oncology, aiming to create small-molecule therapies that can effectively control gene expression in cancer cells.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, founded in 2013. The company specializes in the development, manufacture, and marketing of advanced diagnostic technologies that focus on the detection and analysis of nucleic acid molecules, such as DNA and RNA. In addition to creating reagents for diagnostic tests, Co-Diagnostics offers self-contained lab systems that incorporate diagnostic equipment from other manufacturers. The company also leverages its proprietary technology to design targeted tests for identifying genetic markers, which can be utilized in various industries beyond infectious diseases, while licensing these tests to specific customers.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing microRNA (miRNAs) therapeutics for treating metastatic cancer. The company's core focus lies in its proprietary TTX nanoparticle platform, which enables the intelligent design and effective delivery of RNA therapeutics targeting specific miRNAs. TransCode's lead candidate, TTX-MC138, targets microRNA-10b, a validated biomarker of metastasis across multiple tumor types. By inhibiting this miRNA, TransCode aims to eradicate metastatic tumor cells and combat cancer progression.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

The Mount Sinai School of Medicine in New York, New York, one of the only schools in the nation with a distinctive Department of Medical Education that continually improves the quality of its teaching, offers students a variety of medical academics to shape them into compassionate assistants, professionals and industry leaders. The academics available at Mount Sinai include master's and PhD programs in areas like: * Science and Medicine * Patient Oriented Research Training and Leadership * Biomedical Sciences * Genetic Counseling * Clinical Research Besides its degree-granting programs, Mount Sinai also offers an extensive number of residencies and fellowships, some of which include: * Anesthesiology * Cardiology * Dental Medicine * Emergency Medicine * Hematology and Oncology College life at Mount Sinai is fully-immersed in the medical sciences. All your instruction, provided by medical professionals, will be delivered in a hospital setting, allowing you to familiarize yourself with the many resources and technology used in today's hospitals. Mount Sinai is also home to the Levy Library, which is fully-stocked with myriad medical resources, from journals to professional magazines to textbooks. Since each program has different admissions requirements, please contact Mount Sinai for more information on a program that interests you and your career goals. Tuition assistance is available to students through fellowship programs and Mount Sinai grants and scholarships. For more information federal sources of financial aid, please contact an aid advisor from the school.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. The company focuses on developing therapeutics for Alzheimer's disease and related neurodegenerative disorders, particularly targeting tau proteins. Oligomerix specializes in small molecule drug discovery, with programs centered on tau oligomers and tau protease inhibitors. Additionally, the company creates antibody fragments that serve as biomarkers for drug development, diagnostic, and therapeutic applications. By leveraging its innovative research, Oligomerix aims to identify and validate new drug targets, facilitating the development of disease-modifying treatments for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Talus Bio is a biotechnology startup focused on drug discovery and development, particularly targeting challenging cancer transcription factors. The company employs an innovative approach that integrates functional proteomics, automated biology, and machine learning. Their MARMOT platform utilizes AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics. This platform is designed to advance drug development for gene regulation in oncology, aiming to create small-molecule therapies that can effectively control gene expression in cancer cells.

Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at curing hematologic cancers, solid tumors, and rare genetic diseases. The company’s pipeline includes gene therapy programs for rare genetic disorders and chimeric antigen receptor (CAR) T cell therapies targeting various malignancies. Notable developments include MB-107, a potential curative gene therapy for X-linked severe combined immunodeficiency, and several CAR T therapies such as MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and programs targeting glioblastoma and solid tumors like breast and pancreatic cancers. Mustang Bio has established collaborations with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center to advance its research initiatives. Founded in 2015 and headquartered in New York, the company operates as a subsidiary of Fortress Biotech, Inc.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing microRNA (miRNAs) therapeutics for treating metastatic cancer. The company's core focus lies in its proprietary TTX nanoparticle platform, which enables the intelligent design and effective delivery of RNA therapeutics targeting specific miRNAs. TransCode's lead candidate, TTX-MC138, targets microRNA-10b, a validated biomarker of metastasis across multiple tumor types. By inhibiting this miRNA, TransCode aims to eradicate metastatic tumor cells and combat cancer progression.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally invented at Cornell University, Inso Biosciences enhances the efficiency of processing cellular material. The company's platform is designed to facilitate genomic analysis, including applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. By enabling healthcare and biotechnology companies to effectively separate and isolate cellular components, Inso Biosciences aims to transform the landscape of biological sample preparation.

HDT Bio is a clinical-stage biotechnology company specializing in the development of RNA-based vaccines and therapeutics aimed at combating infectious diseases and oncology. Utilizing its proprietary LION formulation technology, the company creates self-amplifying RNA vaccines and innate immune agonist therapeutics that enhance the stability and delivery of nucleic acids through various administration routes. HDT Bio's innovative approach addresses critical unmet medical needs by activating innate immunity, amplifying adaptive immune responses, and disrupting tumor tight junctions. The company's mission is to accelerate progress in immunotherapy, providing effective solutions not only in leading markets but also in low and middle-income countries, thereby contributing to the global fight against some of the most lethal infectious diseases and cancers.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Coral Genomics, Inc. is a biotechnology company founded in 2018 and headquartered in San Francisco, California. The company focuses on optimizing drug development and deployment by leveraging genomic data from patients. It specializes in developing clinical tests that assist healthcare providers in streamlining prior authorization processes and selecting effective medications tailored to individual patients, particularly in the context of autoimmune conditions like Inflammatory Bowel Disease and Rheumatoid Arthritis. Additionally, Coral Genomics has identified a distinct group of non-responder patients and collaborates with pharmaceutical developers to address the unmet medical needs of this population. By measuring cell responsiveness to drugs and understanding variability across patients, Coral Genomics aims to enhance treatment strategies and improve patient outcomes.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Lactiga is a biotherapeutics company focused on developing innovative biologics aimed at treating and preventing infections, particularly for patients with Primary Immunodeficiency Diseases. By harnessing the therapeutic potential of human milk, Lactiga seeks to combat severe pathogens and improve the quality of life for individuals with rare immunodeficiencies, such as selective IgA deficiency and common variable immunodeficiency. The company's biotherapeutics are designed to prevent mucosal infections, enabling immunodeficient and immunocompromised individuals to lead healthier lives without the need for invasive treatments.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017 by CRISPR pioneer Jennifer Doudna and other key innovators. The company specializes in developing advanced CRISPR technologies, including its proprietary DETECTR platform, which enables the rapid detection of specific nucleic acids associated with various diseases. This platform facilitates diagnostic applications such as cancer screening, bacterial infections, and viral infections, allowing for real-time and simultaneous testing of multiple conditions. In addition to diagnostics, Mammoth Biosciences works on genome editing solutions for therapeutic purposes, targeting areas such as immuno-oncology, autoimmune diseases, and liver disorders. The company aims to democratize disease detection and enhance life science research through innovative, affordable, and efficient tools, while also leveraging its exclusive licensing of various Cas proteins for improved diagnostics and therapeutic applications.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, that focuses on developing a cross-mammal drug discovery platform aimed at treating human diseases. Established in 2018 by a team of scientists with expertise in non-model organisms, the company investigates the biological mechanisms found in hibernating and deep-diving animals to uncover potential therapeutic applications for conditions such as heart disease and neurodegenerative disorders. By leveraging data from a diverse range of species, Fauna Bio aims to identify novel drug targets and facilitate pre-clinical and early clinical testing for new therapeutics, ultimately helping humans recover from serious medical emergencies like trauma, heart attacks, and strokes.

DiamiR is mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care.

SciBac Inc. develops innovative live biotherapeutics aimed at treating antibiotic-resistant diseases while strengthening the microbiome. Founded in 2015 and located in Milpitas, California, the company utilizes a patented MERGE platform that employs directed evolution to enhance the efficacy of beneficial microorganisms. SciBac's initial therapeutics focus on chronic infections associated with cystic fibrosis, targeting pathogens such as Pseudomonas, Staphylococcus, Burkholderia, and non-tuberculous mycobacteria (NTM). By safely transferring beneficial genetic traits, SciBac's approach aims to promote rapid recovery and minimize the risk of reinfections, thereby improving treatment outcomes for patients facing these challenging infections.

Gencove is a software platform that specializes in high-throughput, cost-effective genome sequencing, utilizing low-pass sequencing technology. The company focuses on developing molecular and computational tools aimed at making whole-genome sequencing fast, affordable, and actionable. By setting a new standard in genomics research and diagnostics, Gencove caters to a wide range of industries, including agriculture and pharmaceuticals, thereby providing researchers with accessible genomic data.

Precision Virologics, Inc. is a biotechnology company based in Saint Louis, Missouri, focused on developing biologically targeted vaccines for emerging infectious diseases. Established in 2016, the company utilizes an innovative adenoviral vector technology that incorporates camelid antibodies directed towards activated dendritic cells, effectively delivering proprietary antigen epitopes to target pathogens. One of its key vaccine candidates is PV-ZIKV, designed to combat the Zika virus, which boasts advantages such as a lack of cross-reactivity among flaviviruses and enhanced potency compared to competitors. Precision Virologics aims to provide next-generation vaccines that not only address Zika but also have the potential to target other infectious diseases like chikungunya and dengue, facilitating more effective immune responses.

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care. One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs. CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications). CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

Salk Institute for Biological Studies conducts research on molecular biology and genetics, neurosciences, and plant biology. The research is conducted under the guidance of 59 faculty investigators and more than 850 scientific staff, including visiting scientists, postdoctoral fellows, and graduate students. The institute’s operates to identify therapies and treatments for a range of diseases such as cancer, AIDS, Alzheimer's disease, cardiovascular disorders, anomalies of the brain, and birth defects. Six key areas represent strategic research priorities: chemistry and proteomics, stem cell biology, cell biology, regulatory biology, metabolic research, and computational and theoretical biology. The Institute has trained more than 2,700 scientists, out of which five have won Nobel prizes. Salk is home to nine Howard Hughes Medical Investigators and 14 members of the National Academy of Sciences. NCI Cancer Center, Crick-Jacobs Center, Glenn Center for Aging Research, Helmsley Center for Genomic Medicine, Waitt Advanced Biophotonics Center, and Glenn Center for Aging Research are some of the research centers operated by Salk Institute for Biological Studies. The Salk Institute for Biological Studies was established in the 1960s by Jonas Salk and is based in California, United States.

Quadrant Biosciences Inc. is a life sciences company based in Syracuse, New York, that specializes in developing epigenetic diagnostic solutions and biomarker technologies aimed at addressing significant healthcare challenges. Founded in 2015 and originally named Motion Intelligence Inc., the company focuses on the early identification of neurological disorders, particularly Autism Spectrum Disorder, concussion, and Parkinson's Disease. Quadrant Biosciences collaborates with various research institutions to explore and discover novel biomarker technologies, leveraging its expertise in RNA analysis. The company is committed to improving lives through innovative diagnostic, therapeutic, and virtual care solutions that respond to global health priorities.

Precision Virologics, Inc. is a biotechnology company based in Saint Louis, Missouri, focused on developing biologically targeted vaccines for emerging infectious diseases. Established in 2016, the company utilizes an innovative adenoviral vector technology that incorporates camelid antibodies directed towards activated dendritic cells, effectively delivering proprietary antigen epitopes to target pathogens. One of its key vaccine candidates is PV-ZIKV, designed to combat the Zika virus, which boasts advantages such as a lack of cross-reactivity among flaviviruses and enhanced potency compared to competitors. Precision Virologics aims to provide next-generation vaccines that not only address Zika but also have the potential to target other infectious diseases like chikungunya and dengue, facilitating more effective immune responses.

Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, a cutting-edge platform that integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology is instrumental in identifying and characterizing rare cells that are crucial to understanding biological pathways and diseases. Celldom focuses on applying its innovative solutions primarily in the fields of oncology, immunology, and stem cell biology.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Mission Bio, Inc. is a biotechnology company focused on advancing the study of cellular heterogeneity through its innovative Tapestri Platform, which is the first single-cell multi-omics platform. This platform allows for the simultaneous analysis of genotype and phenotype from individual cells, enabling precise detection of variations in disease progression and treatment responses. Utilizing proprietary microfluidic droplet technology, Mission Bio provides targeted solutions for high-impact applications in fields such as oncology, hematology, and genome editing. The company also offers Tapestri Designer, a cloud-based tool for creating custom single-cell DNA panels, enhancing its capabilities in research and clinical settings. Founded in 2011 and based in South San Francisco, California, Mission Bio was previously known as Torrent Bio, Inc. before rebranding in 2013.

Intact Genomics is a biotech research and development company specializing in large DNA fragment cloning and metagenomic technologies. The company offers a range of life science products and services, including large insert DNA cloning, manipulation, and bacterial artificial chromosome library services. By providing these capabilities, Intact Genomics enables scientists to investigate the genome structure and function of various microorganisms, plants, and animal species. The company is staffed by dedicated scientists and utilizes state-of-the-art equipment in a modern facility located in the Helix Center Biotech Incubator, adjacent to prominent research institutions such as Monsanto and the Donald Danforth Plant Science Center.

Scripps Translational Science Institute works to translate the latest advances in genomics into new diagnostics and treatments. In collaboration with Scripps Genomic Medicine, STSI researchers have collected DNA to generate a comprehensive human DNA bank. These samples could help identify genetic markers for cardiovascular disease, breast, colon and prostate cancers. and other conditions. STSI and Scripps Genomic Medicine investigators have also partnered with Affymetrix, Microsoft, and Navigenics to determine whether personal genomic testing motivates people to make positive lifestyle changes.

Lariat Biosciences, Inc. is an employee-owned biotechnology start-up based at the North Shore Innoventures incubator in Beverly, Massachusetts. The company focuses on early-stage cancer screening and aims to enhance treatment outcomes by developing innovative solutions. Lariat Biosciences markets products and intellectual property derived from extensive cancer research, with core competencies in in-house research and development. Their expertise includes biochemical methods for identifying rare cancer-causing genetic variants and microfluidic chip technologies designed for manipulating and detecting individual cells and DNA molecules. By advancing these technologies, Lariat Biosciences seeks to enable healthcare providers to diagnose and treat cancer at earlier stages, ultimately improving patient care.

American Gene Technologies International Inc., established in 2007 and based in Rockville, Maryland, is a biotechnology company specializing in gene and cell therapeutics. It develops a lentiviral platform for diverse applications, including large and orphan indications, infectious diseases, immuno-oncology, and monogenic disorders. The company's portfolio includes a lead candidate for an HIV functional cure, a novel immuno-oncology approach for stimulating gamma-delta T cells, and a synthetic gene for treating Phenylketonuria (PKU). AGT aims to create long-term value for patients, society, investors, and donors by developing and testing cutting-edge gene therapies to cure some of humanity's worst diseases.

Sangamo Therapeutics is a clinical-stage biotechnology company focused on developing genomic therapies aimed at transforming the lives of patients with serious health conditions. The company employs advanced technologies in genome editing, gene therapy, gene regulation, and cell therapy to create innovative treatment options. Sangamo's diverse product pipeline addresses a range of diseases, including hemophilia, various central nervous system disorders, HIV, lysosomal storage disorders, and hemoglobinopathies. Additionally, the company has prioritized neurology-related programs targeting chronic neuropathic pain, prion disease, and other neurological conditions. Other ongoing initiatives involve treatments for Fabry disease, renal transplant, inflammatory bowel disease, and multiple sclerosis, reflecting Sangamo's commitment to addressing critical unmet medical needs.

SolveBio is a contextual knowledge hub that specializes in genomic intelligence, aimed at supporting pharmaceutical, biotechnology, and diagnostic organizations. The company offers a platform designed to manage, distribute, and access genomic reference data at scale, facilitating the integration of both external and internal genomic information. This platform enables clients to leverage valuable third-party data assets, thereby driving innovation in precision medicine and advancing human health. By providing a real-time dynamic interface, SolveBio empowers organizations to effectively utilize genomic information in their research and development efforts.

Allen Institute for Brain Science is a non-profit medical research organization dedicated to understanding the complexities of bioscience. The organization encompasses three entities, the Allen Institute for Brain Science, Allen Institute for Cell Science, and Paul G. Allen Frontiers Group. Its mission is to accelerate the understanding of how the brain works in health and disease. It creates useful public resources, drive technological and analytical advances, and discover fundamental brain properties through integration of experiments using a big science, team science, and open science approach. Allen Institute for Brain Science was founded on 2003 and is based in Seattle, Washington.

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Circulomics is a biotechnology company based in Maryland, situated within the IMET's Harbor Launch Incubator. The company specializes in developing innovative platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis, with a focus on advancing genomics technologies. Circulomics has created a single molecule analysis system that enhances cancer analysis and diagnosis by streamlining the entire genomics workflow, from sample preparation to assays and detection instruments. This system allows researchers to better characterize their samples prior to sequencing or conducting critical studies, thereby facilitating the research and clinical application of genomics in areas such as expression profiling and biomarker analysis. The company has secured significant funding from the NIH and Maryland TEDCO to support its development efforts.

Novo Biosciences, Inc. is a biotechnology company founded in 2013 and based in Bar Harbor, Maine. The company specializes in the development of small molecule therapies aimed at reversing the damage caused by heart attacks. Its innovative drugs activate dormant genetic mechanisms that promote self-repair and tissue regeneration, allowing both humans and animals to heal more effectively. By harnessing these natural processes, Novo Biosciences seeks to improve health outcomes for patients suffering from life-threatening cardiac conditions.

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.

Circulomics is a biotechnology company based in Maryland, situated within the IMET's Harbor Launch Incubator. The company specializes in developing innovative platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis, with a focus on advancing genomics technologies. Circulomics has created a single molecule analysis system that enhances cancer analysis and diagnosis by streamlining the entire genomics workflow, from sample preparation to assays and detection instruments. This system allows researchers to better characterize their samples prior to sequencing or conducting critical studies, thereby facilitating the research and clinical application of genomics in areas such as expression profiling and biomarker analysis. The company has secured significant funding from the NIH and Maryland TEDCO to support its development efforts.

Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, a cutting-edge platform that integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology is instrumental in identifying and characterizing rare cells that are crucial to understanding biological pathways and diseases. Celldom focuses on applying its innovative solutions primarily in the fields of oncology, immunology, and stem cell biology.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute focused on utilizing genomic and clinical data to advance personalized healthcare. As part of the Inova Center for Personalized Health, ITMI fosters collaboration among researchers, clinicians, and consumers to integrate genomic research into patient care, prevention, and wellness strategies. This innovative approach aims to shift healthcare from a reactive model to a predictive one, enhancing longevity and improving health outcomes. ITMI conducts research that generates extensive genomic and clinical datasets, which are valuable for various fields, including computational biology, psychology, and biomedical research. By analyzing genomic information, ITMI seeks to understand disease onset and promote preventative medicine, thereby enhancing treatment efficacy and minimizing adverse reactions.

Coriell Institute for Medical Research, founded in 1953 and based in Camden, New Jersey, is an independent non-profit research center dedicated to the study of the human genome. Expert staff and pioneering programs in the fields of personalized medicine, cell biology, cytogenetics, genotyping, and biobanking drive Their mission. The emerging field of personalized medicine draws upon a person’s genomic information to tailor treatments and prescription drug dosing to optimize health outcomes. The Coriell Personalized Medicine Collaborative (CPMC) research study is seeking to understand the usefulness of genetic risk and pharmacogenomics in clinical decision-making and healthcare management.

Intact Genomics is a biotech research and development company specializing in large DNA fragment cloning and metagenomic technologies. The company offers a range of life science products and services, including large insert DNA cloning, manipulation, and bacterial artificial chromosome library services. By providing these capabilities, Intact Genomics enables scientists to investigate the genome structure and function of various microorganisms, plants, and animal species. The company is staffed by dedicated scientists and utilizes state-of-the-art equipment in a modern facility located in the Helix Center Biotech Incubator, adjacent to prominent research institutions such as Monsanto and the Donald Danforth Plant Science Center.

TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company employs its proprietary TetraExpress system to produce recombinant human ion channel proteins, which are essential for creating complex therapeutic agents. Among its offerings is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. TetraGenetics specializes in producing difficult-to-express eukaryotic membrane and secretory proteins, including vaccine antigens and monoclonal antibodies, which are crucial for treating various human and animal diseases. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., further enhancing its capabilities in therapeutic innovation.

The Vermont Genetics Network (VGN) is funded by a five-year, $16.5 million award from the National Center for Research Resources (NCRR), and is part of a National Institutes of Health (NIH) initiative called IDeA Networks of Biomedical Research Excellence (INBRE). Under the direction of Dr. Judith Van Houten, the VGN, which links scientists at Castleton State College, Johnson State College, Middlebury College, Norwich University and St. Michael's College to resources at UVM, is designed to provide funding for research, equipment and technology necessary to enhance competitiveness for national funding for genetics research. Other aims of the project include increasing the number of undergraduates who go on to biomedical careers from the baccalaureate colleges, to provide and support bioinformatics capability in the state, and to increase the diversity of biomedical scientists.

Codagenix Inc., established in 2009 and headquartered in Farmingdale, New York, specializes in developing live-attenuated viral vaccines using its proprietary Synthetic Attenuated Virus Engineering (SAVE) platform. This technology involves the rational design of entire viral genomes via synthetic biology to create safe and effective vaccines for various human diseases such as influenza, dengue, respiratory syncytial virus, polio, and others. Additionally, Codagenix offers agricultural and companion animal vaccines.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, that specializes in the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, the company focuses on creating innovative immunotherapies and functional antibodies targeting tumors. Its product pipeline includes IGN523, a humanized monoclonal antibody for various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that enhances the tumor microenvironment. Igenica operates with a strategic oncology research agreement with MedImmune and is supported by a leadership team experienced in antibody drug discovery and clinical development. As of 2017, Igenica operates as a subsidiary of Pierre Fabre Medicament SA, positioning it to leverage additional resources and expertise in the biotherapeutics field.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

The J. Craig Venter Institute is a prominent organization in genomic research, formed in 2006 through the merger of several legacy institutions, including The Institute for Genomic Research and The Center for the Advancement of Genomics. With over 400 scientists and staff, the institute operates from locations in Rockville, Maryland, and San Diego, California, encompassing more than 250,000 square feet of laboratory space. The institute has been at the forefront of genomic advancements for over two decades, initiated by Dr. J. Craig Venter and his teams, who pioneered techniques such as expressed sequence tags and contributed to the sequencing of the first free-living organism, Haemophilus influenzae. The institute's research spans a wide array of fields including genomics medicine, infectious diseases, mammalian genomics, microbial and environmental genomics, and synthetic biology. Recent projects include the sequencing of the first diploid human genome, global ocean sampling expeditions, and the analysis of various infectious disease agents. The institute aims to enhance human health and environmental understanding through its innovative research efforts.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. The company focuses on developing therapeutics for Alzheimer's disease and related neurodegenerative disorders, particularly targeting tau proteins. Oligomerix specializes in small molecule drug discovery, with programs centered on tau oligomers and tau protease inhibitors. Additionally, the company creates antibody fragments that serve as biomarkers for drug development, diagnostic, and therapeutic applications. By leveraging its innovative research, Oligomerix aims to identify and validate new drug targets, facilitating the development of disease-modifying treatments for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Akonni Biosystems, Inc. is a biotechnology company specializing in molecular diagnostics, focusing on the development and manufacture of integrated systems for clinical and life science research markets. Founded in 2003 and headquartered in Frederick, Maryland, the company offers a range of products, including the TruDiagnosis point-of-care testing platform, which allows healthcare professionals to analyze infectious diseases effectively. Its product lineup features TruTip kits for DNA and RNA extraction, TruArray tests for multiplexed molecular diagnostics from various clinical samples, and various MDx instrument platforms such as microarray readers and thermal cyclers. The company’s technologies are particularly relevant for diagnosing infectious diseases, pharmacogenomics, oncology, Alzheimer’s, and cardiovascular conditions, addressing complex health issues including multi-drug-resistant infections.

The Jackson Laboratory, established in 1929 and headquartered in Bar Harbor, Maine, with a facility in California, specializes in mammalian genetics research. It provides international laboratories with scientific services and genetic resources, while also educating students through courses, internships, and collaborative programs. The company's primary focus is discovering the genetic basis for preventing, treating, and curing human diseases across various areas such as cancers, immunology, metabolic diseases, and neurobiology. Additionally, it offers comprehensive mouse breeding and research services tailored to the mouse-based biomedical research community, including breeding management, cryopreservation, phenotyping, and study-ready induced models.

Circulomics is a biotechnology company based in Maryland, situated within the IMET's Harbor Launch Incubator. The company specializes in developing innovative platforms for nucleic acid sample preparation, microRNA profiling, and single molecule analysis, with a focus on advancing genomics technologies. Circulomics has created a single molecule analysis system that enhances cancer analysis and diagnosis by streamlining the entire genomics workflow, from sample preparation to assays and detection instruments. This system allows researchers to better characterize their samples prior to sequencing or conducting critical studies, thereby facilitating the research and clinical application of genomics in areas such as expression profiling and biomarker analysis. The company has secured significant funding from the NIH and Maryland TEDCO to support its development efforts.

Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.

Akonni Biosystems, Inc. is a biotechnology company specializing in molecular diagnostics, focusing on the development and manufacture of integrated systems for clinical and life science research markets. Founded in 2003 and headquartered in Frederick, Maryland, the company offers a range of products, including the TruDiagnosis point-of-care testing platform, which allows healthcare professionals to analyze infectious diseases effectively. Its product lineup features TruTip kits for DNA and RNA extraction, TruArray tests for multiplexed molecular diagnostics from various clinical samples, and various MDx instrument platforms such as microarray readers and thermal cyclers. The company’s technologies are particularly relevant for diagnosing infectious diseases, pharmacogenomics, oncology, Alzheimer’s, and cardiovascular conditions, addressing complex health issues including multi-drug-resistant infections.

Akonni Biosystems, Inc. is a biotechnology company specializing in molecular diagnostics, focusing on the development and manufacture of integrated systems for clinical and life science research markets. Founded in 2003 and headquartered in Frederick, Maryland, the company offers a range of products, including the TruDiagnosis point-of-care testing platform, which allows healthcare professionals to analyze infectious diseases effectively. Its product lineup features TruTip kits for DNA and RNA extraction, TruArray tests for multiplexed molecular diagnostics from various clinical samples, and various MDx instrument platforms such as microarray readers and thermal cyclers. The company’s technologies are particularly relevant for diagnosing infectious diseases, pharmacogenomics, oncology, Alzheimer’s, and cardiovascular conditions, addressing complex health issues including multi-drug-resistant infections.

Akonni Biosystems, Inc. is a biotechnology company specializing in molecular diagnostics, focusing on the development and manufacture of integrated systems for clinical and life science research markets. Founded in 2003 and headquartered in Frederick, Maryland, the company offers a range of products, including the TruDiagnosis point-of-care testing platform, which allows healthcare professionals to analyze infectious diseases effectively. Its product lineup features TruTip kits for DNA and RNA extraction, TruArray tests for multiplexed molecular diagnostics from various clinical samples, and various MDx instrument platforms such as microarray readers and thermal cyclers. The company’s technologies are particularly relevant for diagnosing infectious diseases, pharmacogenomics, oncology, Alzheimer’s, and cardiovascular conditions, addressing complex health issues including multi-drug-resistant infections.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

Akonni Biosystems, Inc. is a biotechnology company specializing in molecular diagnostics, focusing on the development and manufacture of integrated systems for clinical and life science research markets. Founded in 2003 and headquartered in Frederick, Maryland, the company offers a range of products, including the TruDiagnosis point-of-care testing platform, which allows healthcare professionals to analyze infectious diseases effectively. Its product lineup features TruTip kits for DNA and RNA extraction, TruArray tests for multiplexed molecular diagnostics from various clinical samples, and various MDx instrument platforms such as microarray readers and thermal cyclers. The company’s technologies are particularly relevant for diagnosing infectious diseases, pharmacogenomics, oncology, Alzheimer’s, and cardiovascular conditions, addressing complex health issues including multi-drug-resistant infections.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

Sequenom, Inc. is a life sciences company that specializes in developing and commercializing molecular diagnostics testing services focused on women's health and oncology. The company offers a range of laboratory-developed tests (LDTs), including the MaterniT21 PLUS, a noninvasive prenatal test (NIPT) for detecting fetal chromosomal abnormalities, and the VisibiliT LDT, which assesses the relative amounts of chromosomal material in maternal blood samples. Sequenom also provides the MaterniT21 GENOME test for identifying genomic deletions or duplications, as well as the HerediT cystic fibrosis carrier screening test and the SensiGene fetal Rhesus D test. Additionally, the company offers microarray testing under the NextView brand and various carrier screening tests for genetic disorders under the HerediT brand. Founded in 1994 and headquartered in San Diego, California, Sequenom serves physicians and clinical laboratories, and it has established collaborations to enhance its genetic analysis capabilities. As of September 2016, Sequenom operates as a subsidiary of Laboratory Corporation of America Holdings.